Get the Stockscreener App
30.37
0.95%
-0.29
After Hours:
30.35
-0.02
-0.07%
Edgewise Therapeutics Inc stock is traded at $30.37, with a volume of 652.89K.
It is down -0.95% in the last 24 hours and up +25.86% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$30.66
Open:
$30.8
24h Volume:
652.89K
Relative Volume:
0.48
Market Cap:
$3.22B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-19.59
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
+11.70%
1M Performance:
+25.86%
6M Performance:
+126.81%
1Y Performance:
+17.49%
1-Day Range:
$29.38
$30.81
1-Week Range:
$27.78
$31.26
52-Week Range:
$10.60
$31.26
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
30.37 | 3.25B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
EWTX: Phase III readouts and new cardiac programs drive momentum, with strong commercial readiness - TradingView
Assessing Edgewise Therapeutics (EWTX) Valuation After Recent Share Price Momentum - Yahoo Finance
Published on: 2026-02-11 09:46:19 - mfd.ru
Piper Sandler Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A Biotech Gem with 26% Upside Potential - DirectorsTalk Interviews
Edgewise Therapeutics stock hits 52-week high at $30.26 By Investing.com - Investing.com South Africa
Analyst Reiterates Bullish Stance on Edgewise Stock - Intellectia AI
Why Edgewise Therapeutics Stock Crushed the Market on Monday - AOL.com
Edgewise Therapeutics (NASDAQ:EWTX) Sets New 12-Month HighTime to Buy? - MarketBeat
Why Edgewise Therapeutics Stock Crushed the Market on Monday - The Motley Fool
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock - Investing.com
Federated Hermes Inc. Decreases Stock Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - Defense World
Growth Recap: Can Edgewise Therapeutics Inc expand its profit margins2025 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Braveheart Bio names Marc Evanchik CSO - The Pharma Letter
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PR Newswire
Edgewise Therapeutics (EWTX): Analyst Consensus Reveals A 32% Upside Potential - DirectorsTalk Interviews
Dow Update: What analysts say about Edgewise Therapeutics Inc stockJuly 2025 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Down 19.4% in January - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Y Intercept Hong Kong Ltd Invests $929,000 in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Responsive Playbooks and the EWTX Inflection - Stock Traders Daily
EPS Watch: Is Edgewise Therapeutics Inc exposed to currency risksRisk Management & Low Risk Growth Stock Ideas - baoquankhu1.vn
Returns Recap: Will Edgewise Therapeutics Inc benefit from current market trendsWeekly Risk Summary & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Edgewise Therapeutics Reports Q3 2025 Financial Results - MSN
Campbell & CO Investment Adviser LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics director sells $3.39 million in shares By Investing.com - Investing.com India
Edgewise Therapeutics(EWTX.US) Director Sells US$3.4 Million in Common Stock - 富途牛牛
Retail Trends: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2025 Market WrapUp & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Insider Sell: Badreddin Edris Sells 115,471 Shares of Edgewise Therapeutics Inc (EWTX) - GuruFocus
Edgewise Therapeutics (NASDAQ:EWTX) Director Sells $3,399,466.24 in Stock - MarketBeat
Edgewise Therapeutics director sells $3.39 million in shares - Investing.com
Retail Trends: Is Edgewise Therapeutics Inc trading at a discountJuly 2025 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Understanding the Setup: (EWTX) and Scalable Risk - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A 39% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Edgewise Therapeutics, Inc. (EWTX) outlines priorities for 2026 - MSN
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy? - Sahm
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed 2026 Clinical Milestone Update - Sahm
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX - TechStock²
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 7%Should You Buy? - MarketBeat
Technical Analysis: Is Edgewise Therapeutics Inc subject to activist investor interest2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update - Yahoo Finance
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Edris Badreddin | Director |
Jan 21 '26 |
Sale |
29.44 |
115,471 |
3,399,466 |
19,820 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):